DOCSLIB.ORG

Mapping the Landscape of UK Health Data Research & Innovation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mapping the Landscape of UK Health Data Research & Innovation Mapping the Landscape of UK Health Data Research & Innovation A snapshot of activity in 2017 Dr Ekaterini Blaveri October 2017 CONTENTS Foreword 5 1. Background to this review 7 1.1. Aims 8 1.2. Scope and sections 8 1.3. Approach 9 1.4. Challenges 10 1.5. Acknowledgements 10 2. Overview of major informatics investments by Funder 11 2.1. MRC 12 2.1.1. The Farr Institute of Health Informatics Research 12 2.1.2. MRC Medical Bioinformatics initiative 16 2.1.3. MRC Capital Investment in Genomics England Data Infrastructure 19 2.2.1. The NIHR Biomedical Research Centres 21 2.2.2. The NIHR Health Informatics Collaborative programme 22 2.2.3. The NIHR Collaboration for Leadership in Applied Health Research and Care 25 2.3. Department of Health and Social Care 26 2.3.1. Academic Health Science Centres 26 2.3.2. Genomics England | 100,000 Genomes Project 27 2.4. NHS 28 2.4.1. Academic Health Science Networks 28 2.4.2. NHS Genomic Medicine Centres 30 2.4.3. NHS Global Digital Exemplars 31 2.5. ESRC’s investments in Big Data 32 2.5.1. Administrative Data Research Network 32 2.6. EPSRC’s health data research investments 33 3. Key informatics investments by Research Organisation 35 England – East Anglia and Midlands 38 University of Cambridge 41 EMBL-European Bioinformatics Institute 48 Wellcome Sanger Institute 52 University of Birmingham 56 University of Leicester 62 University of Warwick 68 England – London 74 Imperial College London 76 King’s College London 85 London School of Hygiene and Tropical Medicine 94 Queen Mary University of London 98 University College London 103 Mapping the landscape ofMapping the UK Healththe Landscape and Biomedical of UK Health Informatics Data Research & Innovation 3 England – North 110 University of Leeds 112 University of Liverpool 118 University of Manchester 125 Newcastle University 133 University of Sheffield 141 England – South 147 University of Oxford 148 University of Bristol 156 University of Southampton 163 University of Surrey 170 Northern Ireland 176 Queen’s University Belfast 177 Scotland 182 University of Dundee 185 University of Edinburgh 191 University of Glasgow 199 Wales 204 Cardiff University 207 Swansea University 213 ANNEXES 221 Annex 1 222 Biomedical Research Centres research themes 222 Annex 2 226 Further information on ESRC investments in Big Data 226 Annex 3 228 List of abbreviations 228 4 BackgroundContents to this review FOREWORD Over the past decade, the Medical Research Council (MRC) and other major research funders have recognised the huge potential of health data research. Through careful and considerable investment, the funders have collectively built capacity in the sector; and enabled a dramatic change in the use of large patient data and research datasets to help understand, treat and prevent disease. The MRC has prioritised strategic support to this domain of activity, with key investments including: the Farr Institute of Health Informatics Research; MRC Medical Bioinformatics awards: contribution to Genomics England Ltd; and most recently, leading the establishment of the new national institute for health data science, Health Data Research UK (HDR UK). Together with funding from government, universities and charities, these investments have provided a significant step-change in the UK health data landscape across the spectrum, from molecules to man. However, many of these investments are at risk of operating in isolation from each other, with data, knowledge and methods tending to be developed in silos, particularly between the molecular and health informatic fields. Furthermore, the sector still has significant methodological challenges and digital skills shortages. As the volume and complexity of data continues to increase, it’s clear that we need to build on UK expertise, enhance our cutting edge analytical methods, and take a more coordinated approach to managing our unique data resources. Until now, there has been no UK overview of the health data research landscape. The report Mapping the Landscape of UK Health Data Research and Innovation gives a unique window into the major investments made across 26 research organisations throughout the UK. This report was prepared by the MRC to support the funders’ investment decisions into HDR UK. However, it also underscores the importance of health data research for the nation in general – and for science in particular – and will help funders develop a more coordinated and mutually beneficial approach, with an aligned set of delivery mechanisms for future investment. This is a transformational time for the health data research community, with significant activity across the world. The UK not only has a tremendous wealth and variety of health data but also a real strength in analytical skills. This report reveals that the UK has a very real opportunity to be a global leader in health data research and by harnessing this potential could yield huge benefits for our nation’s health and wealth. Dr R S Buckle Chief Science Officer, MRC Mapping the Landscape of UK Health Data Research & Innovation 5 6 Background to this review 1. BACKGROUND TO THIS REVIEW CHAPTER 1 BACKGROUND TO THIS REVIEW 1.1. Aims As part of the activities to establish Health Data Research UK (HDR UK) – previously known as the UK Health and Biomedical Informatics Research Institute – the MRC conducted a health data research and innovation landscape mapping review with the following aims: • To create a broad baseline of current activity in health data research relevant to health/biomedicine and innovation programmes; • To inform the next phase of investments in this area and in particular the new informatics institute (HDR UK), and other related activities, such as opportunities arising from the Life Sciences Industrial Strategy; • To compile qualitative insights that will help create a common understanding of the purpose, likely direction, and impacts of existing investments in health data research across different stakeholders that will result in strengthened partnerships and closer alignment of common objectives across existing and new initiatives; and • To present to the HDR UK Director, and the independent Expert Review Group (ERG), a body of knowledge to help them develop a comprehensive research strategy for HDR UK, including the selection of the research organisation sites that will constitute the institute. 1.2. Scope and sections Scope This review focuses on health data research and innovation investments and activities in the UK, and mainly in England due to the complexity and fragmentation across the breadth of activities in England. It was agreed with the sponsors of this review that if required, it could be broadened to include further investments (e.g. international), and/or deepened to include further analysis on specific investments at a future stage. Sections In its first section, the review provides a top-level view of some key informatics/health data science-related investments from several funders including the: • MRC: Farr Institute of Health Informatics Research; and Medical Bioinformatics awards • NIHR: Health Informatics Collaborative (HIC); and other informatics activities supported through the NIHR Biomedical Research Centres • Department of Health and Social Care England: Academic Health Science Centres • NHS England: Academic Health Science Network; and the National 100,000 Genomes Project • ESRC: Administrative Data Research Centres and Network; and other investments in Big Data • EPSRC: Alan Turing Institute and Health Data Analytics Network In its second section, the review provides an insight analysis of the confidential Statements of Interest (SoI) submitted from the different Research Organisations (ROs) in response to a targeted call issued in December 2016 to express their interest to become an HDR UK substantive or partner site. 8 Background to this review Out of scope This review does not include activities or investments on: • computational tools and platforms developed by the digital healthcare industry; • detailed description of data resources and population cohorts; and • information governance and data access processes and policies. 1.3. Approach The review staff (Dr Ekaterini Blaveri) used a combination of desk research and stakeholder communications to gain an understanding of the key UK programmes in health data research. Going forward the use of surveys, structured interviews; and workshop(s) with key opinion leaders could be considered to gain a deeper understanding of certain activities. It should be noted that the material searched could potentially be much more extensive, since aspects of research collaboration are referenced over a wide range of publications. However, because of the limited time available to this review, information was collated predominately from the funders of key programmes. Extracting insights from the Statements of Interest received from UK Research Organisations in response to the December 2016 call The MRC office received SoIs from 26 ROs interested in becoming a substantive site of HDR UK. These were subdivided into seven geographical clusters, to make easier to identify the regional strengths and interconnections. As the information requested from the ROs was very high-level, a modified “SWOT” analysis – (Strengths, Translational and Innovation Capabilities, Opportunities and Gaps – STOG) was performed to synthesise meaningful insights from the SoI and address the following questions: Strengths • What the organisation already does well? • What resources (both tangible and intangible)
Load more

Recommended publications
  • Undergraduate Board
    1 September 2006 Undergraduate Board To consider QABME: the School of Medicine, University of Leicester for 2005/06 Issue 1. Review of the assessment of Leicester Medical School in the academic year 2005 to 2006. Recommendations 2. The Undergraduate Board are invited to agree: a. In the academic year 2005/06, the School of medicine, University of Leicester met appropriately for that stage the standards of Tomorrow’s Doctors, subject to meeting the requirements in paragraphs 15 a to c. Further Information 3. Coreen Beckford 020 7189 5397 [email protected] Cara Talbot 020 7189 5284 [email protected] Introduction 4. This is the final report to the Education Committee on the quality assurance programme for the School of Medicine, University of Leicester for 2006. 5. The visiting team appointed by the Education Committee to undertake the quality assurance visits included the following individuals. Throughout the rest of this report the GMC visiting team is referred to as the visiting team: Professor Reg Jordan (team leader) Mr Philip Brown Dr Jennie Ciechan Mrs Susan Hobbs Professor Peter McCrorie Dr Philip Milner Professor Trudie Roberts Dr Bruno Rushforth Dr Martin Talbot 6. Miss Coreen Beckford and Ms Cara Talbot supported the visiting team. Our programme of visits in 2005/06 7. The GMC visiting team attended the School on 6 occasions: 14 February 2006, 2 March 2006, 18 May 2006, 23 May 2006, 14 June 2006 and 21 June 2006. 8. The following field work was undertaken: a. Meetings with various members of the School. b. Observation of the clinical examinations.
    [Show full text]
  • 100000 Genomes and Genomics England
    100,000 Genomes & Genomics England Tim Hubbard Genomics England King’s College London, King’s Health Partners Wellcome Trust Sanger Institute Global Leaders in Genomic Medicine Washington 8-9th January 2014 UK Health System 101 • Four separate health services – NHS England – NHS Wales – NHS Scotland – Health & Social Care in Northern Ireland (HSC) • NHS (England) – ~1.4 million employees – ~£110 billion annual budget • Structure in England changed 1st April 2013 https://www.gov.uk/government/organisations/department-of-health Linking Health data to Research Clinical Data Healthcare Professional World Genotype Electronic Health Record Whole Genome Sequencing Phenotype Electronic Genomic Biology Health Data World Records Reference Genotype and genome sequence Phenotype ~3 gigabytes relationship capture EBI: repositories (petabytes of genome sequence data) Human sequence data Sanger: sequencing repositories (1000 genomes, uk10K) Steps in UK towards E-Health Research, Genomic Medicine • Health data to Research – 2006 Creation of OSCHR • Increase coordination between funders: MRC and NIHR – 2007 OSCHR E-health board • Enable research access to UK EHR data • Build capacity for research on EHR data • Genomics to Health – 2009 House of Lords report on Genomic Medicine – 2010 Creation of Human Genomic Strategy Group (HGSG) 2011: UK Life Sciences Strategy No10: http://www.number10.gov.uk/news/uk-life-sciences-get-government-cash-boost/ BIS/DH: http://www.dh.gov.uk/health/2011/12/nhs-adopting-innovation/ Linking Health data to Research Clinical Data
    [Show full text]
  • D2.1 State of the Art and Requirements Analysis V1 Project Deliverable
    Collective Wisdom Driving Public Health Policies Del. no. – D2.1 State of the Art and Requirements Analysis v1 Project Deliverable This project has received funding from the European Union’s Horizon 2020 Programme (H2020-SC1-2016-CNECT) under Grant Agreement No. 727560 D2.1 State of the Art and Requirements 29/09/2017 Analysis v1 D2.1 State of the Art and Requirements Analysis v1 Work Package: WP2 Due Date: 01/09/2017 Submission Date: 29/09/2017 Start Date of Project: 01/03/2017 Duration of Project: 36 Months Partner Responsible of Deliverable: SIEMENS Version: 1.0 Final Draft Ready for internal Review Status: Task Leader Accepted WP leader accepted Project Coordinator accepted Dimosthenis Kyriazis (UPRC), Ilias Maglogiannis (UPRC), Christos Xenakis (UPRC), Argyro Mavrogiorgou (UPRC), Athanasios Kiourtis (UPRC), George Peppas (UPRC), Carlos Cavero (ATOS), Santiago Aso (ATOS), Antonio De Nigro (ENG), Francesco Torelli (ENG), Domenico Martino (ENG), George Moldovan (SIEMENS), Kosmin- Septimiu Nechifor (SIEMENS), Salvador Tortajada Velert (HULAFE), Sokratis Nifakos (KI), Tanja Tomson (KI), Jan Janssen (DFKI), Serge Autexier (DFKI), Petrina Smyrli (BIO), Andreas Menychtas (BIO), Author name(s): Christos Panagopoulos (BIO), Chris Orton (ICE), Usman Wajid (ICE), Thanos Kosmidis (CRA), Ricardo Jimenez-Peris (LXS), Patricio Martinez (LXS), Marta Patino-Martinez (UPM), Rafael Fernandez (UPM), Michael Boniface (IT-INN), Vegard Engen (IT- INN), Daniel Burns (IT-INN), Mitja Lustrek (JSI), Maroje Soric (ULJ), Patrick Weber (EFMI), John Mantas (EFMI),
    [Show full text]
  • Functional Effects Detailed Research Plan
    GeCIP Detailed Research Plan Form Background The Genomics England Clinical Interpretation Partnership (GeCIP) brings together researchers, clinicians and trainees from both academia and the NHS to analyse, refine and make new discoveries from the data from the 100,000 Genomes Project. The aims of the partnerships are: 1. To optimise: • clinical data and sample collection • clinical reporting • data validation and interpretation. 2. To improve understanding of the implications of genomic findings and improve the accuracy and reliability of information fed back to patients. To add to knowledge of the genetic basis of disease. 3. To provide a sustainable thriving training environment. The initial wave of GeCIP domains was announced in June 2015 following a first round of applications in January 2015. On the 18th June 2015 we invited the inaugurated GeCIP domains to develop more detailed research plans working closely with Genomics England. These will be used to ensure that the plans are complimentary and add real value across the GeCIP portfolio and address the aims and objectives of the 100,000 Genomes Project. They will be shared with the MRC, Wellcome Trust, NIHR and Cancer Research UK as existing members of the GeCIP Board to give advance warning and manage funding requests to maximise the funds available to each domain. However, formal applications will then be required to be submitted to individual funders. They will allow Genomics England to plan shared core analyses and the required research and computing infrastructure to support the proposed research. They will also form the basis of assessment by the Project’s Access Review Committee, to permit access to data.
    [Show full text]
  • Genomics England and Sciencewise Evaluation of a Public Dialogue On
    Genomics England and Sciencewise Evaluation of a public dialogue on Genomic Medicine: Time for a new social contract? Evaluation report June 2019 Quality Management URSUS Consulting Ltd has quality systems which have been assessed and approved to BS EN IS9001:2008 (certificate number GB2002687). Creation / Revision History Issue / revision: 3 Date: 19/6/2019 Prepared by: Anna MacGillivray Authorised by: Anna MacGillivray Project number: U.158 File reference: Genomics England/genomic medicine draft evaluation report 19.6.2019 URSUS CONSULTING LTD 57 Balfour Road London N5 2HD Tel. 07989 554 504 www.ursusconsulting.co.uk _________________________________________________________________________________________ URSUS CONSULTING GENOMICS ENGLAND AND SCIENCEWISE 2 Glossary of Acronyms ABI Association of British Insurers AI Artificial Intelligence APBI Association of British Pharmaceutical Industry BEIS (Department of) Business, Energy and Industrial Strategy BME Black and Minority Ethnic CMO Chief Medical Officer CSO (NHS) Chief Scientific Officer DA Devolved Administration DHSC Department of Health and Social Care FTE Full Time Equivalent GDPR General Data Protection Regulation GE Genomics England GG Generation Genome report GMS Genomic medicine service GMC General Medical Council NHS National Health Service OG Oversight Group REA Rapid Evidence Assessment SEG Socio economic group SGP Scottish Genomes Partnership SoS Secretary of State SSAC Scottish Science Advisory Committee SLT Senior Leadership Team UKRI UK Research and Innovation WGS Whole Genome Sequencing _________________________________________________________________________________________ URSUS CONSULTING GENOMICS ENGLAND AND SCIENCEWISE 3 EXECUTIVE SUMMARY Introduction This report of the independent evaluation of a public dialogue on Genomic Medicine: Time for a new social contract? has been prepared by URSUS Consulting Ltd on behalf of Genomics England (GE) and Sciencewise1.
    [Show full text]
  • The Proposed Merger of Ealing Hospital NHS Trust and the North West London Hospitals NHS Trust Full Business Case Version 15
    The proposed merger of Ealing Hospital NHS Trust and The North West London Hospitals NHS Trust Full Business Case Version 15: 20th June 2014 Table of Contents Table of Contents ................................................................................................ i List of Tables ...................................................................................................... v List of Figures .................................................................................................. vii Abbreviations .................................................................................................. viii 0. Executive Summary ................................................................................... 1 0.1 Background ........................................................................................................ 1 0.2 The case for change ........................................................................................... 1 0.3 London North West Healthcare – What will day 1 feel like? ................................ 2 0.4 London North West Healthcare - What will be different for patients? .................. 3 0.5 Conclusion ......................................................................................................... 3 1. Introduction................................................................................................. 4 1.1 Background to the FINAL business case ............................................................ 4 1.2 Strategic context ................................................................................................
    [Show full text]
  • PULSE: Speaker Biographies March 2019
    PULSE: Speaker Biographies March 2019 Supported by @BIA_UK www.bioindustry.org In order of appearance: Dr Barbara Domayne-Hayman Entrepreneur-in-residence, Francis Crick Institute, CBO, Autifony Therapeutics Ltd and formerly Chairman, Puridify Barbara has worked on the commercial side of life sciences for thirty years, first in a large organisation (ICI/Zeneca/AstraZeneca), before transitioning to the entrepreneurial world of biotech. Barbara joined the Francis Crick Institute in January 2018 as Entrepreneur-in- residence. She is also Chief Business officer of Autifony, where she is responsible for strategic partnering, fundraising and commercial aspects of drug development for CNS disorders. In December 2017 Autifony signed a major collaboration with Boehringer Ingelheim. Barbara was also Chair of Puridify, a UCL spin-out with a breakthrough biotherapeutics purification technology, which was acquired by GE in November 2017. She chairs the LifeArc Seed Fund investment committee, and is on the Cambridge Enterprise Seed Fund Investment Committee. Previously, Barbara was CEO of Stabilitech, and she was Commercial Director at Arrow Therapeutics until the company was acquired by AstraZeneca. Barbara was also Senior Business Development Manager at Celltech. Barbara has a BA and D Phil in Chemistry from the University of Oxford, and is a Sloan Fellow from London Business School. Steve Bates, OBE CEO, BioIndustry Association Since his appointment as Chief Executive of the BioIndustry Association in 2012, Steve has led major BIA campaigns for, amongst other things, improved access to finance, the refilling of the Biomedical Catalyst, anti-microbial resistance and the opportunity the sector presents to generalist long term investors. Steve champions the adaptive pathway approach to the licensing of new drugs, the need for Early Access and is particularly proud of the working relationship the BIA has established with the UK’s leading medical research charities.
    [Show full text]
  • London: an Innovation Hub for Health & Life Sciences Through
    LONDON: AN INNOVATION HUB FOR HEALTH & LIFE SCIENCES THROUGH THE APPLICATION OF DATA AND AI SUPPORTED BY Next page Access the market: 19 from NHS to Biopharma CONTENTS Foreword 3 The NHS adoption of AI technologies 20 This is an interactive guide, London’s key strengths 4 l Spotlight on UCLPartners 21 so click on the title to jump to any section. An Innovative Biopharma Cluster 22 An ecosystem built for growth 5 l Case study - MultiplAI 23 Access to funding 6 Government support 7 An accessible, diverse 24 l Case study - Kheiron Medical 9 and data-rich environment Diverse population and data 24 London’s life sciences clusters 10 Partner with the Health Data 25 The Knowledge Quarter 11 Research Hubs Whitechapel: Barts Life Sciences Hub 12 l Spotlight on DATA-CAN HDR 26 White City Innovation District 13 Southbank to Sutton 14 London’s resilient COVID-19 response 27 l Case study - InstaDeep 28 Talent and educational excellence 15 Existing talent 16 How can we help 29 The next generation 17 How London & Partners can support 29 l Case study - PEP Health 18 How MedCity can support 29 2 Contents page FOREWORD COVID-19 has accelerated data-driven innovation across often siloed organisations. Similarly, policy is being the globe, with artificial intelligence and data science at developed to overcome legacy systems and regulations, the forefront of addressing human disease and health. which will underpin and speed up innovations. The coronavirus pandemic has led to increased acceptance of new technologies with strong buy-in from all corners Not only can bioinformatics and use of healthcare Allen Simpson Neelam Patel data lead to better health systems and outcomes, this of the life sciences and healthcare sector determined to CEO also has the potential to create many new jobs Acting CEO keep this momentum going.
    [Show full text]
  • Extensive Microbial Diversity Within the Chicken Gut Microbiome Revealed by Metagenomics and Culture
    Extensive microbial diversity within the chicken gut microbiome revealed by metagenomics and culture Rachel Gilroy1, Anuradha Ravi1, Maria Getino2, Isabella Pursley2, Daniel L. Horton2, Nabil-Fareed Alikhan1, Dave Baker1, Karim Gharbi3, Neil Hall3,4, Mick Watson5, Evelien M. Adriaenssens1, Ebenezer Foster-Nyarko1, Sheikh Jarju6, Arss Secka7, Martin Antonio6, Aharon Oren8, Roy R. Chaudhuri9, Roberto La Ragione2, Falk Hildebrand1,3 and Mark J. Pallen1,2,4 1 Quadram Institute Bioscience, Norwich, UK 2 School of Veterinary Medicine, University of Surrey, Guildford, UK 3 Earlham Institute, Norwich Research Park, Norwich, UK 4 University of East Anglia, Norwich, UK 5 Roslin Institute, University of Edinburgh, Edinburgh, UK 6 Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Atlantic Boulevard, Banjul, The Gambia 7 West Africa Livestock Innovation Centre, Banjul, The Gambia 8 Department of Plant and Environmental Sciences, The Alexander Silberman Institute of Life Sciences, Edmond J. Safra Campus, Hebrew University of Jerusalem, Jerusalem, Israel 9 Department of Molecular Biology and Biotechnology, University of Sheffield, Sheffield, UK ABSTRACT Background: The chicken is the most abundant food animal in the world. However, despite its importance, the chicken gut microbiome remains largely undefined. Here, we exploit culture-independent and culture-dependent approaches to reveal extensive taxonomic diversity within this complex microbial community. Results: We performed metagenomic sequencing of fifty chicken faecal samples from Submitted 4 December 2020 two breeds and analysed these, alongside all (n = 582) relevant publicly available Accepted 22 January 2021 chicken metagenomes, to cluster over 20 million non-redundant genes and to Published 6 April 2021 construct over 5,500 metagenome-assembled bacterial genomes.
    [Show full text]
  • Pocketbook for You, in Any Print Style: Including Updated and Filtered Data, However You Want It
    Hello Since 1994, Media UK - www.mediauk.com - has contained a full media directory. We now contain media news from over 50 sources, RAJAR and playlist information, the industry's widest selection of radio jobs, and much more - and it's all free. From our directory, we're proud to be able to produce a new edition of the Radio Pocket Book. We've based this on the Radio Authority version that was available when we launched 17 years ago. We hope you find it useful. Enjoy this return of an old favourite: and set mediauk.com on your browser favourites list. James Cridland Managing Director Media UK First published in Great Britain in September 2011 Copyright © 1994-2011 Not At All Bad Ltd. All Rights Reserved. mediauk.com/terms This edition produced October 18, 2011 Set in Book Antiqua Printed on dead trees Published by Not At All Bad Ltd (t/a Media UK) Registered in England, No 6312072 Registered Office (not for correspondence): 96a Curtain Road, London EC2A 3AA 020 7100 1811 [email protected] @mediauk www.mediauk.com Foreword In 1975, when I was 13, I wrote to the IBA to ask for a copy of their latest publication grandly titled Transmitting stations: a Pocket Guide. The year before I had listened with excitement to the launch of our local commercial station, Liverpool's Radio City, and wanted to find out what other stations I might be able to pick up. In those days the Guide covered TV as well as radio, which could only manage to fill two pages – but then there were only 19 “ILR” stations.
    [Show full text]
  • Minutes of the Proceedings
    MINUTES OF THE PROCEEDINGS at the Thirty‐sixth Meeting of the COUNCIL of the IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE The Thirty‐sixth Meeting of the Council was held in the Council Room, 170 Queen’s Gate, South Kensington Campus, Imperial College London, at 10:00 a.m. on Friday, 16th May 2014, when there were present: The Baroness Manningham‐Buller (Chair), Professor A. Anandalingam, Mr. C. Brinsmead, Dame Ruth Carnall, Mrs. P. Couttie, Professor M.J. Dallman, Mr. P. Dilley, Mr. D. Goldsmith, Professor N. Gooderham, Professor Dame Julia Higgins, Professor D.P.A. Kelleher, Ms. J.R. Lomax, Professor J. Magee, Mr. J. Newsum, Mr. S. Newton, Ms. K. Owen, Mr. M. Sanderson, Professor J Stirling, the President & Rector and the Clerk to the Court and Council. Apologies Mr. I. Conn. MINUTES Council – 7th February 2014 1. The Minutes of the thirty‐fifth Meeting of the Council, held on Friday, 7th February 2014, were taken as read, confirmed and signed. CHAIR’S REPORT 2. The Chair advised members that, following his appointment as Chair of the Chelsea and Westminster Hospital NHS Foundation Trust, Sir Thomas Hughes‐Hallett had resigned as a co‐opted member of the Council on 11 February. PRESIDENT & RECTOR’S REPORT 3. The President & Rector reported that this year’s Imperial Festival, held on 9th and 10th May, had received many visitors at the South Kensington campus to enjoy the various demonstrations, talks 1 Council 16th May 2014 and other activities on offer. What had started as a relatively modest pilot project in 2012 to explore how Imperial College London might share its research with more people had now evolved into a large‐scale and prominent annual fixture in the College’s calendar.
    [Show full text]
  • 1985517720.Pdf
    JOURNAL OF BACTERIOLOGY, Jan. 2009, p. 347–354 Vol. 191, No. 1 0021-9193/09/$08.00ϩ0 doi:10.1128/JB.01238-08 Copyright © 2009, American Society for Microbiology. All Rights Reserved. Complete Genome Sequence and Comparative Genome Analysis of Enteropathogenic Escherichia coli O127:H6 Strain E2348/69ᰔ† Atsushi Iguchi,1 Nicholas R. Thomson,2 Yoshitoshi Ogura,1,3 David Saunders,2 Tadasuke Ooka,3 Ian R. Henderson,4 David Harris,2 M. Asadulghani,1 Ken Kurokawa,5 Paul Dean,6 Brendan Kenny,6 Michael A. Quail,2 Scott Thurston,2 Gordon Dougan,2 Tetsuya Hayashi,1,3 Julian Parkhill,2 and Gad Frankel7* Division of Bioenvironmental Science, Frontier Science Research Center,1 and Division of Microbiology, Department of Infectious Diseases, Faculty of Medicine,3 University of Miyazaki, Miyazaki, Japan; Pathogen Genomics, The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdom2; School of Immunity and Infection, University of Downloaded from Birmingham, Birmingham, United Kingdom4; Department of Biological Information, School and Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, Kanagawa, Japan5; Institute of Cell and Molecular Biosciences, University of Newcastle, Newcastle upon Tyne, United Kingdom6; and Centre for Molecular Microbiology and Infection, Division of Cell and Molecular Biology, Imperial College London, London, United Kingdom7 Received 5 September 2008/Accepted 15 October 2008 Enteropathogenic Escherichia coli (EPEC) was the first pathovar of E. coli to be implicated in human disease; however, no EPEC strain has been fully sequenced until now. Strain E2348/69 (serotype O127:H6 belonging to E. http://jb.asm.org/ coli phylogroup B2) has been used worldwide as a prototype strain to study EPEC biology, genetics, and virulence.
    [Show full text]